Tomorrow's Cures. Developed. Delivered.

Rapidly growing cell and mRNA therapy programs frequently hit bottlenecks due to a shortage of right-sized manufacturing capacity and long lead times for both research-grade and GMP material. Kincellis addresses these supply gaps by combining deep cell therapy experience with flexible mRNA development and manufacturing across three purpose-built U.S. facilities. Drug developers can choose between customizable, scalable processes—taking DNA templates through in vitro transcription, purification, and filtration—or automated, construct-agnostic production utilizing the Ntensify® platform to scale out from a single personalized dose to commercial volumes. Supporting both ex vivo gene editing and emerging in vivo CAR-T applications, these integrated capabilities streamline CMC development from early clinical stages through commercial launch.
Download the full brochure to explore specific facility footprints, modality expertise, and the upcoming roadmap for LNP encapsulation and fill-finish services.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.